Synopsis of recent research by authors named "Shidai Mu"
- Shidai Mu's research primarily focuses on the genomic and immune landscape of cancers, emphasizing the roles of various molecular pathways and factors, such as ABL1 kinase and APE1, in tumor progression and treatment resistance across different cancer types including multiple myeloma and esophageal adenocarcinoma.
- Recent studies have highlighted the impact of genomic instability and the epithelial-to-mesenchymal transition (EMT) on cancer outcomes, with findings suggesting that dysregulation of homologous recombination pathways contributes significantly to cancer mechanism and patient prognosis.
- Mu's work also extends to the development of prognostic models and therapeutic approaches, such as enhancing natural killer (NK) cell function in the treatment of multiple myeloma and constructing nomograms for predicting survival in rare lymphomas, thereby integrating clinical and immunological insights to improve patient management.
